#WomenInSTEM have been breaking new ground - yesterday, today, and tomorrow. On the 10th International Day of Women and Girls in Science, we share the stories of our colleagues Ingrid, Ling, and Zeena. See what working in science means for them: go.boehringer.com/wEaFd
#LifeForward
#LifeForward
February 11, 2025 at 9:28 AM
#WomenInSTEM have been breaking new ground - yesterday, today, and tomorrow. On the 10th International Day of Women and Girls in Science, we share the stories of our colleagues Ingrid, Ling, and Zeena. See what working in science means for them: go.boehringer.com/wEaFd
#LifeForward
#LifeForward
🧪 Meet our colleague Dr. Zeena Williams whose team ensures the quality of new compounds made for patients in clinical trials. It was her teacher who instilled her passion for chemistry.
Learn how Zeena supports future women in #science: go.boehringer.com/kq2IX
#LifeForward #WomenInSTEM #chemsky
Learn how Zeena supports future women in #science: go.boehringer.com/kq2IX
#LifeForward #WomenInSTEM #chemsky
February 27, 2025 at 1:02 PM
🧪 Meet our colleague Dr. Zeena Williams whose team ensures the quality of new compounds made for patients in clinical trials. It was her teacher who instilled her passion for chemistry.
Learn how Zeena supports future women in #science: go.boehringer.com/kq2IX
#LifeForward #WomenInSTEM #chemsky
Learn how Zeena supports future women in #science: go.boehringer.com/kq2IX
#LifeForward #WomenInSTEM #chemsky
At 37, Samantha was diagnosed with non-small cell #lungcancer (NSCLC).
With support from her husband Justin and care team, she learned about #biomarker testing 🧪 to understand her cancer’s unique profile.
#LifeForward #Oncology #Medsky
With support from her husband Justin and care team, she learned about #biomarker testing 🧪 to understand her cancer’s unique profile.
#LifeForward #Oncology #Medsky
August 15, 2025 at 2:24 PM
At 37, Samantha was diagnosed with non-small cell #lungcancer (NSCLC).
With support from her husband Justin and care team, she learned about #biomarker testing 🧪 to understand her cancer’s unique profile.
#LifeForward #Oncology #Medsky
With support from her husband Justin and care team, she learned about #biomarker testing 🧪 to understand her cancer’s unique profile.
#LifeForward #Oncology #Medsky
Rabies is fatal once symptoms appear – but it’s preventable. Supported by our Stop Rabies program, Ecuador is accelerating efforts to eliminate dog‑mediated rabies by 2030 through vaccination, education and stronger surveillance.
Read more 🧪👉 go.boehringer.com/HlQ7Y
#OneHealthSummit #LifeForward
Read more 🧪👉 go.boehringer.com/HlQ7Y
#OneHealthSummit #LifeForward
April 9, 2026 at 8:09 AM
Rabies is fatal once symptoms appear – but it’s preventable. Supported by our Stop Rabies program, Ecuador is accelerating efforts to eliminate dog‑mediated rabies by 2030 through vaccination, education and stronger surveillance.
Read more 🧪👉 go.boehringer.com/HlQ7Y
#OneHealthSummit #LifeForward
Read more 🧪👉 go.boehringer.com/HlQ7Y
#OneHealthSummit #LifeForward
#NEWS: The U.S. Food and Drug Administration (FDA) has approved the first new treatment for idiopathic pulmonary fibrosis (#IPF) in over a decade. 🧪
Learn more here: go.boehringer.com/rtx-w
#LifeForward
Learn more here: go.boehringer.com/rtx-w
#LifeForward
October 9, 2025 at 10:02 AM
#NEWS: The U.S. Food and Drug Administration (FDA) has approved the first new treatment for idiopathic pulmonary fibrosis (#IPF) in over a decade. 🧪
Learn more here: go.boehringer.com/rtx-w
#LifeForward
Learn more here: go.boehringer.com/rtx-w
#LifeForward
The immune system has the remarkable ability to identify and eliminate cancer cells.
Our oncology research includes the investigation of T-cell engagers, focusing on leveraging immune mechanisms in cancer therapy.
Learn more 🧪: go.boehringer.com/Ki82v
#LifeForward #Oncology
Our oncology research includes the investigation of T-cell engagers, focusing on leveraging immune mechanisms in cancer therapy.
Learn more 🧪: go.boehringer.com/Ki82v
#LifeForward #Oncology
October 20, 2025 at 7:57 AM
The immune system has the remarkable ability to identify and eliminate cancer cells.
Our oncology research includes the investigation of T-cell engagers, focusing on leveraging immune mechanisms in cancer therapy.
Learn more 🧪: go.boehringer.com/Ki82v
#LifeForward #Oncology
Our oncology research includes the investigation of T-cell engagers, focusing on leveraging immune mechanisms in cancer therapy.
Learn more 🧪: go.boehringer.com/Ki82v
#LifeForward #Oncology
🧪#NEWS: We are looking forward to working with
@saliprobiotech.bsky.social's team of scientists, to develop new medicines addressing challenging drug targets to transform patients' lives. #science #LifeForward
@saliprobiotech.bsky.social's team of scientists, to develop new medicines addressing challenging drug targets to transform patients' lives. #science #LifeForward
PRESS RELEASE: Salipro Biotech and @boehringerglobal.bsky.social enter research and license agreement to accelerate multiple Boehringer Ingelheim pipeline programs
Access the full press release at:
www.salipro.com/news/press-r...
#Salipro #MembraneProteins #Collaboration #Pharma #Biotech
Access the full press release at:
www.salipro.com/news/press-r...
#Salipro #MembraneProteins #Collaboration #Pharma #Biotech
March 13, 2025 at 2:34 PM
🧪#NEWS: We are looking forward to working with
@saliprobiotech.bsky.social's team of scientists, to develop new medicines addressing challenging drug targets to transform patients' lives. #science #LifeForward
@saliprobiotech.bsky.social's team of scientists, to develop new medicines addressing challenging drug targets to transform patients' lives. #science #LifeForward
#NEWS: Today, the @fda.gov approved our orally administered therapy for patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment. This marks the first approved targeted therapy for this use.
Learn more: go.boehringer.com/VHCH-
#LifeForward
Learn more: go.boehringer.com/VHCH-
#LifeForward
February 26, 2026 at 6:46 PM
#NEWS: Today, the @fda.gov approved our orally administered therapy for patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment. This marks the first approved targeted therapy for this use.
Learn more: go.boehringer.com/VHCH-
#LifeForward
Learn more: go.boehringer.com/VHCH-
#LifeForward
#NEWS: New pooled phase III data in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) presented at the European Respiratory Society (ERS) Congress 2025: go.boehringer.com/rdYYD 🧪
#ERS2025 #LifeForward
#ERS2025 #LifeForward
September 29, 2025 at 6:46 AM
#NEWS: New pooled phase III data in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) presented at the European Respiratory Society (ERS) Congress 2025: go.boehringer.com/rdYYD 🧪
#ERS2025 #LifeForward
#ERS2025 #LifeForward
#NEWS: Pivotal FIBRONEER™-IPF and FIBRONEER™-ILD phase III full data in IPF and PPF presented at #ATS2025 and published in @nejm.org. IPF and PPF are serious conditions that can cause irreversible lung damage and continued decline in lung function. 🧪 👉 go.boehringer.com/1fG0l
#LifeForward
#LifeForward
May 19, 2025 at 4:26 PM
#NEWS: Pivotal FIBRONEER™-IPF and FIBRONEER™-ILD phase III full data in IPF and PPF presented at #ATS2025 and published in @nejm.org. IPF and PPF are serious conditions that can cause irreversible lung damage and continued decline in lung function. 🧪 👉 go.boehringer.com/1fG0l
#LifeForward
#LifeForward
#NEWS: Ten of our oncology abstracts will be presented at #ESMO25, sharing our ongoing research efforts in hard-to-treat cancers.
🧪 Learn more: go.boehringer.com/GCZ1
#LifeForward #Oncology
🧪 Learn more: go.boehringer.com/GCZ1
#LifeForward #Oncology
October 10, 2025 at 2:48 PM
#NEWS: Ten of our oncology abstracts will be presented at #ESMO25, sharing our ongoing research efforts in hard-to-treat cancers.
🧪 Learn more: go.boehringer.com/GCZ1
#LifeForward #Oncology
🧪 Learn more: go.boehringer.com/GCZ1
#LifeForward #Oncology
Looking for #WomenInSTEM in history books? Our site in Ochsenhausen, Germany, has been founded by two women in 1971. Hear more from our colleague Dr. Ingrid Rapp who joined the lab in the 90s and was part of the transformation into a biotech company: go.boehringer.com/C_8j5
#LifeForward
#LifeForward
February 13, 2025 at 2:12 PM
Looking for #WomenInSTEM in history books? Our site in Ochsenhausen, Germany, has been founded by two women in 1971. Hear more from our colleague Dr. Ingrid Rapp who joined the lab in the 90s and was part of the transformation into a biotech company: go.boehringer.com/C_8j5
#LifeForward
#LifeForward
#NEWS: The @fda.gov has approved our new treatment for progressive pulmonary fibrosis (PPF) in adults. The approval provides hope to people living with this life-threatening condition.
Learn more here: go.boehringer.com/SYRTX
#LifeForward #PulmonaryFibrosis
Learn more here: go.boehringer.com/SYRTX
#LifeForward #PulmonaryFibrosis
December 19, 2025 at 5:30 PM
#NEWS: The @fda.gov has approved our new treatment for progressive pulmonary fibrosis (PPF) in adults. The approval provides hope to people living with this life-threatening condition.
Learn more here: go.boehringer.com/SYRTX
#LifeForward #PulmonaryFibrosis
Learn more here: go.boehringer.com/SYRTX
#LifeForward #PulmonaryFibrosis
#NEWS for media: Our targeted cancer therapy has been approved in the U.S. for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer by the U.S. @fda.gov.
Learn more here 👉: www.boehringer-ingelheim.com/human-health...
#LifeForward #Oncology
Learn more here 👉: www.boehringer-ingelheim.com/human-health...
#LifeForward #Oncology
August 8, 2025 at 8:10 PM
#NEWS for media: Our targeted cancer therapy has been approved in the U.S. for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer by the U.S. @fda.gov.
Learn more here 👉: www.boehringer-ingelheim.com/human-health...
#LifeForward #Oncology
Learn more here 👉: www.boehringer-ingelheim.com/human-health...
#LifeForward #Oncology
#NEWS: Our latest oncology research in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) has been presented at #ESMO25.
These advancements have the potential to fulfill patients’ unmet needs.
🧪 Find out more: go.boehringer.com/FU9K9
#LifeForward #Oncology
These advancements have the potential to fulfill patients’ unmet needs.
🧪 Find out more: go.boehringer.com/FU9K9
#LifeForward #Oncology
October 17, 2025 at 2:05 PM
#NEWS: Our latest oncology research in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) has been presented at #ESMO25.
These advancements have the potential to fulfill patients’ unmet needs.
🧪 Find out more: go.boehringer.com/FU9K9
#LifeForward #Oncology
These advancements have the potential to fulfill patients’ unmet needs.
🧪 Find out more: go.boehringer.com/FU9K9
#LifeForward #Oncology
Living with cancer, the small, positive moments often have the biggest impact.
We're here to celebrate these 'Big Little Things': small victories, time with loved ones, and everyday joys.
🧪 Discover how these moments make a difference: go.boehringer.com/YomJY
#LifeForward #Oncology
We're here to celebrate these 'Big Little Things': small victories, time with loved ones, and everyday joys.
🧪 Discover how these moments make a difference: go.boehringer.com/YomJY
#LifeForward #Oncology
October 16, 2025 at 9:48 AM
Living with cancer, the small, positive moments often have the biggest impact.
We're here to celebrate these 'Big Little Things': small victories, time with loved ones, and everyday joys.
🧪 Discover how these moments make a difference: go.boehringer.com/YomJY
#LifeForward #Oncology
We're here to celebrate these 'Big Little Things': small victories, time with loved ones, and everyday joys.
🧪 Discover how these moments make a difference: go.boehringer.com/YomJY
#LifeForward #Oncology
#NEWS: New Phase II trial results in primary focal segmental glomerulosclerosis (FSGS) published in The Lancet.
Primary FSGS is a rare, progressive kidney disease, which can end in kidney failure.
Read more 👉 go.boehringer.com/VecpO
#LifeForward
Primary FSGS is a rare, progressive kidney disease, which can end in kidney failure.
Read more 👉 go.boehringer.com/VecpO
#LifeForward
January 28, 2026 at 6:38 AM
#NEWS: New Phase II trial results in primary focal segmental glomerulosclerosis (FSGS) published in The Lancet.
Primary FSGS is a rare, progressive kidney disease, which can end in kidney failure.
Read more 👉 go.boehringer.com/VecpO
#LifeForward
Primary FSGS is a rare, progressive kidney disease, which can end in kidney failure.
Read more 👉 go.boehringer.com/VecpO
#LifeForward
#NEWS: Full data from two Phase III trials in people living with #obesity presented at #ADA2026.
These results show potential to address patients’ unmet needs in obesity and liver health.
Read more 👉 go.boehringer.com/4hch
#LifeForward #ADASciSessions
These results show potential to address patients’ unmet needs in obesity and liver health.
Read more 👉 go.boehringer.com/4hch
#LifeForward #ADASciSessions
June 7, 2026 at 6:40 PM
#NEWS: Full data from two Phase III trials in people living with #obesity presented at #ADA2026.
These results show potential to address patients’ unmet needs in obesity and liver health.
Read more 👉 go.boehringer.com/4hch
#LifeForward #ADASciSessions
These results show potential to address patients’ unmet needs in obesity and liver health.
Read more 👉 go.boehringer.com/4hch
#LifeForward #ADASciSessions
#NEWS: China’s National Medical Products Administration (NMPA) has approved our new treatment for progressive #PulmonaryFibrosis (PPF). 🧪
In a field where milestones are scarce, today signals meaningful momentum for the PPF community.
Learn more: go.boehringer.com/ao0kp
#LifeForward
In a field where milestones are scarce, today signals meaningful momentum for the PPF community.
Learn more: go.boehringer.com/ao0kp
#LifeForward
December 10, 2025 at 10:58 AM
#NEWS: China’s National Medical Products Administration (NMPA) has approved our new treatment for progressive #PulmonaryFibrosis (PPF). 🧪
In a field where milestones are scarce, today signals meaningful momentum for the PPF community.
Learn more: go.boehringer.com/ao0kp
#LifeForward
In a field where milestones are scarce, today signals meaningful momentum for the PPF community.
Learn more: go.boehringer.com/ao0kp
#LifeForward
Every minute, 30 people worldwide suffer a #stroke. Our colleague Horst was one of them. His story highlights how swift action can significantly improve the chances of long-term recovery: go.boehringer.com/UHT3
#LifeForward
#LifeForward
February 21, 2025 at 9:34 AM
Every minute, 30 people worldwide suffer a #stroke. Our colleague Horst was one of them. His story highlights how swift action can significantly improve the chances of long-term recovery: go.boehringer.com/UHT3
#LifeForward
#LifeForward
#NEWS: Our targeted therapy has received approval in China as a first-line treatment for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), making it an initial therapy option.
🧪Learn more: go.boehringer.com/_xdMW
#LifeForward #Oncology #LungCancer
🧪Learn more: go.boehringer.com/_xdMW
#LifeForward #Oncology #LungCancer
May 22, 2026 at 7:41 AM
#NEWS: Our targeted therapy has received approval in China as a first-line treatment for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), making it an initial therapy option.
🧪Learn more: go.boehringer.com/_xdMW
#LifeForward #Oncology #LungCancer
🧪Learn more: go.boehringer.com/_xdMW
#LifeForward #Oncology #LungCancer
#NEWS: We’re launching a new vaccine to help prevent mastitis, one of the most common diseases in dairy cows. Designed for a two-dose administration, it offers early and long‑lasting protection.
Learn more here: go.boehringer.com/m8oFO
#LifeForward
Learn more here: go.boehringer.com/m8oFO
#LifeForward
April 13, 2026 at 10:01 AM
#NEWS: We’re launching a new vaccine to help prevent mastitis, one of the most common diseases in dairy cows. Designed for a two-dose administration, it offers early and long‑lasting protection.
Learn more here: go.boehringer.com/m8oFO
#LifeForward
Learn more here: go.boehringer.com/m8oFO
#LifeForward
#NEWS: Together with Eko Health Inc., we’re launching an AI based solution to detect, visualize and grade heart murmurs in dogs. Eko Vet+™ | CANINEBEAT® AI supports veterinarians in identifying murmurs that may otherwise go unnoticed.
Learn more: go.boehringer.com/6EMA5
#VetTech #LifeForward
Learn more: go.boehringer.com/6EMA5
#VetTech #LifeForward
April 29, 2026 at 10:45 AM
#NEWS: Together with Eko Health Inc., we’re launching an AI based solution to detect, visualize and grade heart murmurs in dogs. Eko Vet+™ | CANINEBEAT® AI supports veterinarians in identifying murmurs that may otherwise go unnoticed.
Learn more: go.boehringer.com/6EMA5
#VetTech #LifeForward
Learn more: go.boehringer.com/6EMA5
#VetTech #LifeForward
#NEWS: Our Phase III trial in people living with #obesity or overweight without type 2 diabetes has met its co-primary endpoints. Obesity is linked to liver disease, type 2 diabetes and cardiovascular disease.
Read more 👉 go.boehringer.com/Nsw9
#LifeForward
Read more 👉 go.boehringer.com/Nsw9
#LifeForward
April 28, 2026 at 6:12 AM
#NEWS: Our Phase III trial in people living with #obesity or overweight without type 2 diabetes has met its co-primary endpoints. Obesity is linked to liver disease, type 2 diabetes and cardiovascular disease.
Read more 👉 go.boehringer.com/Nsw9
#LifeForward
Read more 👉 go.boehringer.com/Nsw9
#LifeForward